494 related articles for article (PubMed ID: 15989998)
1. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
[TBL] [Abstract][Full Text] [Related]
2. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
4. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Murray B; Allen Z; Lief JH; Galbreath RW
Brachytherapy; 2004; 3(1):22-9. PubMed ID: 15110310
[TBL] [Abstract][Full Text] [Related]
5. Brachytherapy-related dysuria.
Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Lief JH
BJU Int; 2005 Mar; 95(4):597-602. PubMed ID: 15705087
[TBL] [Abstract][Full Text] [Related]
6. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
[TBL] [Abstract][Full Text] [Related]
7. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
[TBL] [Abstract][Full Text] [Related]
8. The impact of radiation dose to the urethra on brachytherapy-related dysuria.
Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Lief JH; Reed DJ
Brachytherapy; 2005; 4(1):45-50. PubMed ID: 15737906
[TBL] [Abstract][Full Text] [Related]
9. Selecting patients with pretreatment postvoid residual urine volume less than 100 mL may favorably influence brachytherapy-related urinary morbidity.
Beekman M; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW
Urology; 2005 Dec; 66(6):1266-70. PubMed ID: 16360455
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting for urinary incontinence after prostate brachytherapy.
McElveen TL; Waterman FM; Kim H; Dicker AP
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
[TBL] [Abstract][Full Text] [Related]
11. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
Kollmeier MA; Stock RG; Cesaretti J; Stone NN
J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274
[TBL] [Abstract][Full Text] [Related]
12. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.
Thomas C; Keyes M; Liu M; Moravan V
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):447-55. PubMed ID: 18395357
[TBL] [Abstract][Full Text] [Related]
13. Temporal resolution of urinary morbidity following prostate brachytherapy.
Merrick GS; Butler WM; Lief JH; Dorsey AT
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):121-8. PubMed ID: 10758313
[TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
[TBL] [Abstract][Full Text] [Related]
16. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
[TBL] [Abstract][Full Text] [Related]
17. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
18. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
19. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]